Immunomic Therapeutics is a company that looks to develop biotechnologies through an immunotherapy platform. The company was founded in 2005, in Rockville, Maryland, United States.
The company studies investigational technologies that can assist in altering how immunotherapy solutions are utilized across a range of diseases. They work with solutions for cancer, allergies, and infectious diseases. The company studies nucleic acid immunotherapy platforms to change how immunotherapies are used for cancer and other uses.
Immunomic Therapeutics is developing treatments such as their ITI-1000 and ITI-1001 for GBM, ITI-2000 for HPV and tumors, ITI-3000 for Merkel Cell Carcinoma, ITI-4000 for NPC and Gastic issues, ITI-5000 for Neoantigens, ITI-6000 for HCC, ITI-7000 for bladder infections, and their ITI-COVID-19 for SARS-CoV-2. They have partnered with entities such as PharmaJet, Zenoq, and Replicate.
They have also created a platform called UNITE (Universal Intracellular Targeted Expression). The platform has lysosomal targeting technology, use adjuvants, antigen selection and optimizations, and offer various delivery methods.